Table 1

Comparison of patients classified as having RA at baseline and after 18-month follow-up according to the 1987 and 2010 criteria

At baselineAfter 18-month follow-up
1987 Criteria (n=47)2010 Criteria (n=87)1987 Criteria (n=96)2010 Criteria (n=92)
Age, years; median (IQR)60 (50–69)58 (46–68)60 (47–70)59 (45–68)
Female; n (%)24 (51)53 (61)53 (55)56 (61)
RF positive; n (%)26 (55)49 (56)44 (46)49 (53)
Anti-CCP positive; n (%)28 (60)51 (59)48 (50)51 (55)
Eventual outcome (after follow-up); n (%)
 Definitive non-RA diagnosis3 (6)7 (8)
 Self-limiting illness5 (11)16 (18)12 (13)19 (21)
DMARD use within first 18 months; n (%)
 Methotrexate31 (66)50 (58)60 (63)51 (55)
 Other9 (19)15 (17)18 (19)16 (17)
  • Anti-CCP, anticyclic citrullinated peptide antibody; DMARD, disease-modifying antirheumatic drug; RA, rheumatoid arthritis; RF, rheumatoid factor.